Body weight variability, or yo-yo dieting, raises the risk of diabetic kidney disease (DKD) in individuals with type 1 diabetes, regardless of BMI and traditional risk factors. A study analyzed data from 1432 T1D patients and found that higher weight fluctuations were significantly associated with a decline in kidney function.
Body weight variability or cycling, also known as “yo-yo dieting,” increases the risk for diabetic kidney disease in patients with type 1 diabetes , independent of body mass index and traditional risk factors.Body weight cycling, defined as the repeated loss and gain of weight over the years, has been associated with an increased risk for cardiovascular events in both the general population and patients with diabetes.
They calculated four indices of intraindividual body weight variability using annual body weight data of the patients, choosing variability independent of the mean as the primary index.
DIABETES KIDNEY DISEASE WEIGHT VARIABILITY TYPE 1 DIABETES CARDIOVASCULAR HEALTH
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Yo-yo dieting may significantly increase kidney disease risk in people with type 1 diabetesBody-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI) and other traditional risk factors, according to a new study.
Read more »
Glucarpidase Enhances Kidney Recovery in Methotrexate-Associated Acute Kidney InjuryOutcomes in methotrexate-induced kidney injury have shown improvement through treatment with the enzyme glucarpidase.
Read more »
Oversleeping May Increase Your Risk of Dying from Chronic Kidney Disease, Study FindsA new study from Japan reveals that sleeping for eight to nine hours a night is linked to a significantly higher risk of death from chronic kidney disease. The study also suggests that longer sleep durations might be a sign of underlying health issues that contribute to kidney disease.
Read more »
FDA approves Ozempic to help reduce risk of worsening chronic kidney diseaseOzempic, the GLP-1 drug initially approved by the FDA to treat type 2 diabetes, was recently OK'd to also help reduce risks linked to chronic kidney disease.
Read more »
FDA approves Ozempic to help reduce risk of worsening chronic kidney diseaseOzempic, the GLP-1 drug initially approved by the FDA to treat type 2 diabetes, was recently OK'd to also help reduce risks linked to chronic kidney disease.
Read more »
Ozempic Approved to Reduce Kidney Risk in Type 2 DiabetesThe FDA has approved Ozempic for reducing the risk of serious kidney complications in people with type 2 diabetes. This new approval allows doctors to prescribe Ozempic specifically to lower the risk of kidney disease progression. The approval comes as a breakthrough after years of limited progress in this area, and demand for the drug is expected to increase.
Read more »